Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma
Part 1: To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with R/R FL.

Part 2: To characterize the activity of acalabrutinib alone or in combination with rituximab in subjects with R/R MZL, as measured by ORR.

Part 3: To characterize the safety of acalabrutinib in combination with rituximab and lenalidomide in subjects with R/R FL
Non Hodgkin Lymphoma
DRUG: acalabrutinib|DRUG: rituximab (IV)|DRUG: Lenalidomide
Number of Participants With Treatment Emergent Adverse Events (AEs), Number of participants who had experienced at least one treatment emergent AE, From first dose of study drug to within 30 days of last dose of study drug
An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects with B-cell Non-Hodgkin Lymphoma